When Every Countermeasure Works

Vitamin D with probiotics. A bacterial preparation. Spirulina. Ultrasound. Estrogen. Plant compounds tested against bone loss. A probiotic strain altered by spaceflight. Thirteen records, spanning different interventions, organisms, exposures, and outcomes, arrived at the same destination in Gastronaut's current gut-health evidence set. Every one with an extractable direction reported benefit.

A perfect record is tempting because it appears to simplify a complicated field. It can also be the moment when scrutiny should increase. If unrelated countermeasures tested in rats, mice, cells, terrestrial humans, and analog environments all seem to work, what has been measured: biological promise, a publication system, a search process, a coding rule, or some mixture of all four?

The denominator supplies the first answer. Gastronaut's usable gut set contains 72 studies. Twenty-four were coded as carrying a manipulable intervention or countermeasure. Thirteen stated a record-level direction that could be classified as benefit, null, or harm. All 13 were beneficial. The remaining 11 did not provide an extractable direction and were excluded. They were kept visible in the 24-record direction map rather than quietly converted into nulls or discarded.

Under a simple model in which benefit and non-benefit are equally likely among direction-bearing records, 13 concordant results yield a two-sided exact sign-test probability of 0.000244140625, or 0.00024 when rounded to five decimal places. The calculation says that the pattern is unusual under that model. It does not estimate an effect size, show that the interventions share a mechanism, or establish that any of them will help a crew member in space.

The underlying studies resist a common efficacy estimate. Some used hindlimb-unloaded rodents. Some used simulated microgravity. One followed humans on a 24-day Antarctic voyage by ship. One administered a spaceflight-derived bacterial strain to terrestrial mice. The outcomes included intestinal homeostasis, microbial composition, bone density, muscle atrophy, colitis, kidney structure, and pharyngeal flora. Calling all thirteen “benefit” preserves a directional observation while compressing almost everything that determines clinical or mission meaning.

One explanation is genuine success. Investigators may have selected interventions with good prior evidence and paired them with sensitive models. Another is publication selection, in which null or harmful results are less likely to appear. A third is retrieval selection. Titles and abstracts announcing improvement are easy to find and code, while ambiguous or null directions may remain inside inaccessible full text. A fourth is coding compression. One successful primary endpoint can give an entire record a favorable label even when secondary endpoints are mixed.

The current analysis cannot choose among those explanations. It also carries a source-specific boundary. Twelve of the 13 favorable records resolve through a DOI. The remaining 2008 Russian-language record is identifiable as PubMed PMID 19008843. Its indexed English abstract reports reduced opportunistic pathogen titers and increased pharyngeal symbionts during a 24-hour simulated-microgravity exposure, which supports the benefit code. Independent translation of the full Russian text remains pending. The entire first-pass map also awaits an independent second-coder check.

These caveats do not make the pattern meaningless. They change its meaning. Thirteen favorable directions across heterogeneous records are a diagnostic of the evidence system before they are a conclusion about countermeasures. The next task is to search specifically for what the present set does not show: registered but unpublished studies, conference results, dissertations, agency reports, adverse endpoints, and full tables hidden behind positive abstracts.

Null results are especially valuable in a lunar program because they prevent scarce missions from repeating an attractive mistake. A compound that changes microbiome composition without improving barrier function narrows the next experiment. An intervention that helps one endpoint and worsens another defines a trade. A treatment that fails under storage, dosing, or crew-time constraints can still save mass and schedule later. Reporting failure is not merely a norm of open science. It is a way to return operational value from an experiment whose biological hypothesis did not survive.

NASA can reduce this ambiguity in future lunar nutrition and microbiome research by requiring the intervention, comparator, primary endpoint, direction rule, and analysis window to be declared before data collection. Complete endpoint tables should preserve null and adverse results. Exposure labels should prevent a simulated rodent finding from drifting into a human flight claim. Diet, medications, antibiotics, sample timing, microbial function, host physiology, and operational burden should travel with compositional data.

Fresh crops make that reporting standard more important, not less. A harvested food can change fiber, vitamins, polyphenols, moisture, texture, appetite, and menu choice at the same time. A microbiome shift cannot be assigned confidently to the crop unless the study measures the portion consumed, batch composition, background diet, microbial function, intestinal-barrier response, and at least one host outcome. A long list of taxa may be scientifically interesting while remaining operationally undecidable.

Gastronaut would apply that discipline to any proposed ORCA nutrition study. ORCA is a ground-stage crop platform at approximately TRL 3 to 4 and has not flown. Gastronaut does not claim that an ORCA crop prevents intestinal, microbiome, bone, muscle, or kidney effects. The immediate contribution is methodological: expose the complete direction map, retain the nondirectional records, and make failures as reusable as successes.

A practical NASA engagement would begin with an audit rather than an intervention choice. Gastronaut is prepared to place the full direction table and coding note before Human Research Program nutrition and microbiome investigators. Together, reviewers could test the row-level classifications and define a common template for null, adverse, and mixed endpoints in lunar countermeasure studies.

The goal is not to make the evidence less optimistic. It is to make optimism survive contact with the missing rows. In a trustworthy countermeasure program, a perfect scoreboard is not the green light. It is the lamp that tells researchers where to look next.

Research foundation and evidence boundaries

The 13-of-13 pattern and exact sign-test probability are Gastronaut-owned results from a 72-study usable set containing 24 countermeasure-coded records. Eleven of those 24 lacked an extractable record-level direction and were excluded from the sign test, not treated as nulls. The studies are too heterogeneous for pooled efficacy inference. Reporting or selection bias is plausible but unproven. Independent full-text translation of PMID 19008843 and a second-coder review of the complete map remain pending. No present ORCA health-effect claim is made.

References

1. Liu et al. "CB001 Bioactive Compounds Mitigate Intestinal Immune Dysregulation Induced by Simulated Microgravity and Radiation via B Cells Modulation." Pharmaceutical Biology, 2026. https://doi.org/10.1080/13880209.2026.2675166
2. Wang et al. "Probiotic Properties of a Spaceflight-Induced Mutant Lactobacillus plantarum SS18-50 in Mice." 2022. https://doi.org/10.2174/1871530321666210917163719
3. Sun et al. "Lactobacillus reuteri F-9-35 Prevents DSS-Induced Colitis by Inhibiting Proinflammatory Gene Expression and Restoring the Gut Microbiota in Mice." Journal of Food Science, 2018. https://doi.org/10.1111/1750-3841.14326
4. Srivastava et al. "Probiotics Maintain the Gut Microbiome Homeostasis During Indian Antarctic Expedition by Ship." Scientific Reports, 2021. https://doi.org/10.1038/s41598-021-97890-4
5. Huang et al. "Co-delivery of Vitamin D and Probiotics and Their Synergistic Improvement of Intestinal Functions in Simulated Microgravity Rats." 2026. https://doi.org/10.1016/j.ijbiomac.2026.153575
6. Ranade et al. "Gut Microbiome-Targeted Intervention Ameliorates Structural and Transcriptomic Changes in the Kidney of a Hindlimb-Unloaded Mouse Model." Animal Microbiome, 2026. https://doi.org/10.1186/s42523-025-00503-y
7. Yu et al. "Abdominal LIPUS Ameliorates Simulated Microgravity-Induced Skeletal Muscle Atrophy via the Gut-Muscle Axis." npj Microgravity, 2025. https://doi.org/10.1038/s41526-025-00514-8
8. Zhang et al. "Effects of Bifidobacterium lactis BLa80 on Fecal and Mucosal Flora and SCF/c-kit Signaling in Simulated Microgravity Rats." World Journal of Gastroenterology, 2025. https://doi.org/10.3748/wjg.v31.i1.96199
9. Zhang et al. "Spirulina platensis Components Mitigate Bone Density Loss Induced by Simulated Microgravity." Food Chemistry, 2024. https://doi.org/10.1016/j.foodchem.2024.141361
10. Qi et al. "Cordymin Alleviates Osteoporosis Induced by Hindlimb Unloading via the Gut-Microelements-Bone Axis." BMC Musculoskeletal Disorders, 2023. https://doi.org/10.1186/s12891-023-07057-7
11. Niu et al. "Asperosaponin VI Protects Against Bone Loss Due to Hindlimb Unloading Through Microbial Dysbiosis and the 5-HT Pathway." Calcified Tissue International, 2023. https://doi.org/10.1007/s00223-022-01057-w
12. Yang et al. "Estrogen Inhibits the Overgrowth of Escherichia coli in the Rat Intestine Under Simulated Microgravity." Molecular Medicine Reports, 2018. https://doi.org/10.3892/mmr.2017.8109
13. Kriukov et al. "Effect of Short-Term Application of a Lactate-Containing Probiotic on the Pharyngeal Microflora in Healthy Subjects." Vestnik Otorinolaringologii, 2008. PubMed PMID 19008843